Death

Westray Law 20th anniversary: ‘A historic failure’

Retrieved on: 
Friday, March 29, 2024
CLC, Westray Mine, Failure, Health, Congress, Criminal code, Memory, United Steelworkers, Police, Death, Parliament, USW, Survivor, The Criminal Code, Injury, Miner, Fatality, Law

“The overwhelming majority of these workplace fatalities and injuries were preventable, yet the Westray Law has rarely been used to prosecute employers and hold them criminally accountable.

Key Points: 
  • “The overwhelming majority of these workplace fatalities and injuries were preventable, yet the Westray Law has rarely been used to prosecute employers and hold them criminally accountable.
  • The Westray Law was named in memory of 26 coal miners who were killed in the Westray Mine explosion in Nova Scotia in 1992.
  • “The Westray Law was a historic achievement that promised greater corporate accountability for workplace safety and greater protection for workers,” says Allen Martin, whose brother Glenn, 35, was one of the miners killed in the Westray Mine explosion.
  • On the Westray Law’s 20th anniversary, the USW, supported by the CLC and other labour federations, is ramping up the campaign to pressure governments to take action to address the failure to enforce the law.

Beyond Meat® Unveils New and Expanded Line of Beyond Crumbles, Now Certified by the American Heart Association’s Heart-Check Program and the American Diabetes Association’s Better Choices for Life Program

Retrieved on: 
Thursday, March 28, 2024
American Heart Association, Health, LDL, Certification, Cardiovascular disease, Taste, BYND, Nutrition, TMAO, Nutrient, Diabetes, American Journal, American Cancer Society, Stroke, Crumble, Beyond Meat, Sodium, Food, Death, Risk, Breakfast, Diet, American Diabetes Association, Beyond, Reference Daily Intake, Lunch, Cholesterol, American Heart, Dietary supplement

Convenient and easy to prepare, simply sauté the crumbles for four minutes in a skillet before adding them to your favorite dish or sauce.

Key Points: 
  • Convenient and easy to prepare, simply sauté the crumbles for four minutes in a skillet before adding them to your favorite dish or sauce.
  • Beyond Crumbles’ strong nutritional profile, coupled with its simple and clean ingredient list, earned the product certification by the American Heart Association’s Heart-Check program and the American Diabetes Association’s Better Choices for Life program,” said Beyond Meat Founder and CEO Ethan Brown.
  • As part of Beyond Meat’s commitment to innovating for human health, this announcement follows Beyond Steak’s earlier certifications by the American Heart Association and the American Diabetes Association .
  • With 1.2 million Americans diagnosed with diabetes every year , the Better Choices for Life Program uses the American Diabetes Association’s evidence-based guidelines to help consumers make informed choices about the foods they purchase.

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Retrieved on: 
Thursday, March 28, 2024
COCP, MERS, Research, SARS, Enzyme, Drug discovery, Influenza, CFO, COVID-19, Lung, Coronavirus, RNA, Gastroenteritis, G&A, Death, SARS-CoV-2, Trial of the century, IND, Disease, World Health Organization, Post-exposure prophylaxis, Clinical trial, CDC, Safety, Pharmacokinetics, Cocrystal, Therapy, FDA, Pharmaceutical industry

Our drug-discovery process focuses on the highly conserved regions of the viral enzymes and inhibitor-enzyme interactions at the atomic level.

Key Points: 
  • Our drug-discovery process focuses on the highly conserved regions of the viral enzymes and inhibitor-enzyme interactions at the atomic level.
  • Cocrystal reported unrestricted cash as of December 31, 2023 of $26.4 million, compared with $37.1 million as of December 31, 2022.
  • Net cash used in operating activities for 2023 was $14.7 million, compared with $21.4 million for 2022.
  • The Company had working capital of $25.0 million and 10.2 million common shares outstanding as of December 31, 2023.

IMUNON Reports 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 28, 2024
Transfer, Ovarian cancer, Immunotherapy, Patient, Lung, Vaccine, Good manufacturing practice, Sale, CMC, IND, Bangladesh Technical Education Board, IPR, Investment, Clinical trial, Neoplasm, Research, Primate, DNA, NOL, MD Anderson Cancer Center, Trial of the century, ITT, Safety, MRD, Interim, Silicon Valley Bank, Vaccination, Food, CMOS, Elsevier, CD8, Drug discovery, SVB, CRS, University, Death, SARS-CoV-2, Earnings call, Lassa mammarenavirus, PFS, Immunoglobulin G, FDA, OS, CD4, Temperature, Progression-free survival, COVID-19, Mouse, Messenger, Human, Wistar Institute, Hospital

LAWRENCEVILLE, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today reported financial results for the year ended December 31, 2023. The Company also provided an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary mono- or multi-cistronic DNA plasmid and a synthetic DNA delivery technology for the expression of pathogen antigens in preclinical studies for the development of next-generation vaccines.

Key Points: 
  • “We remain on track to report topline results mid-year from the OVATION 2 Study with IMNN-001 in advanced ovarian cancer.
  • In September 2023, the Company announced interim PFS and OS data with IMNN-001 in its OVATION 2 Study.
  • The Company is hosting a conference call to provide a business update, discuss 2023 financial results and answer questions at 10:00 a.m. Eastern time today.
  • To participate in the call, please dial 866-777-2509 (Toll-Free/North America) or 412-317-5413 (International/Toll) and ask for the IMUNON 2023 Earnings Call.

By 2035, Canada could have the most enviable healthcare system in the world if obesity is recognized as a chronic disease, predicts Obesity Canada

Retrieved on: 
Wednesday, March 27, 2024
Health, Conditional sentence, Cardiovascular disease, Conference, Obesity, Pressure, Notifiable disease, Hypertension, Diabetes, Accreditation, Research, Obesity Canada, Science, Death, Cancer, BMI, Pharmaceutical industry

The multiplication factor of obesity: Obesity is intricately linked with various chronic diseases, including cardiovascular diseases, diabetes, certain cancers, and joint problems, placing an immense burden on individual health and healthcare systems.

Key Points: 
  • The multiplication factor of obesity: Obesity is intricately linked with various chronic diseases, including cardiovascular diseases, diabetes, certain cancers, and joint problems, placing an immense burden on individual health and healthcare systems.
  • Obesity can be treated effectively; we know what to do: Canada is a global leader in obesity research and clinical expertise.
  • The Canadian Obesity Clinical Practice Guidelines are globally recognized as the gold standard and Canadian experts are highly regarded as thought leaders.
  • Revolutionizing our healthcare system: By officially recognizing obesity as a chronic disease and investing in evidence-based strategies, Canada (provincial and territorial health ministries) has the potential to lead the world in healthcare excellence within the next decade, predicts Obesity Canada.

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

Retrieved on: 
Wednesday, March 27, 2024
Research, Finkelstein, Arrhythmia, Stroke, Annual report, Certification, Myocardial infarction, BCDA, Partnership, Patient, The Study, Morph, Mortality, Form 10-K, Security (finance), Death, Heart transplantation, Quality of life, Doctor of Philosophy, Heart failure, Therapy, Heart, Safety, Data, Medicare, FDA, Helix, Arrest, Hospital, Pharmaceutical industry

The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights with call details below.

Key Points: 
  • The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights with call details below.
  • The Company anticipates completing follow-up in the trial and preparing this dataset on 115 randomized patients enrolled with a minimum of one-year follow-up for final lock in the fourth quarter of 2024.
  • BioCardia has had discussions on partnering its CardiAMP therapy for other clinical indications and continues to explore partnerships worldwide.
  • All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioCardia call.

PLI Treatise Addresses Income Tax Opportunities and Traps for Transfers After Death

Retrieved on: 
Wednesday, March 27, 2024
Code, Income tax, Trust, Death, Life insurance

A new treatise from PLI Press, Income Taxation of Property Acquired from a Decedent , is an essential resource for tax practitioners and others who advise on estate and income tax matters, covering planning opportunities and traps to consider before and after death.

Key Points: 
  • A new treatise from PLI Press, Income Taxation of Property Acquired from a Decedent , is an essential resource for tax practitioners and others who advise on estate and income tax matters, covering planning opportunities and traps to consider before and after death.
  • “With proper, informed planning, discrepancies under the Code can be cured, traps can be avoided, and traditional estate planning techniques combined with additional income tax planning can lead to favorable results for both estate and income tax,” says the treatise’s author, Matthew S. Beard.
  • Comprehensively addressing income tax issues related to transfers after death, the publication’s topics include the exclusion from gross income under I.R.C.
  • § 1014, the application of these rules to common trust and entity structures in estate planning, substantiation, and planning opportunities and potential traps for the unwary to consider before and after death.

Green Builder Media’s Virtual Sustainability Symposium Is Coming Up ... Reserve Your Spot!

Retrieved on: 
Wednesday, March 27, 2024
Physics, Climate change, RMI (energy organization), Growth, Steel, Symposium, ESG, Politics, Symposium (Plato), Hope, Death, Wind, Nature, Life, Carbon, Outline, Green Builder Media, Trane Technologies, Whirlpool Corporation, Progress, Hydrogen, Apathy, Economics, Renewable energy

The Symposium, which is free to all attendees, will be held virtually over two days from 12:00-3:00 pm ET each day.

Key Points: 
  • The Symposium, which is free to all attendees, will be held virtually over two days from 12:00-3:00 pm ET each day.
  • Green Builder Media's dynamic CEO, Sara Gutterman, unveils the hottest sustainability trends revolutionizing the landscape for building professionals, homeowners, and businesses.
  • (If you want to read more details about the symposium before registering, check out the webpage here. )
  • A heartfelt thank you to Trane Technologies and Whirlpool Corporation for their continued support of our annual Sustainability Symposium, as well as their comprehensive commitment to corporate sustainability.

Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID

Retrieved on: 
Wednesday, March 27, 2024
COVID, Type, COVID-19, Patient, Heart rate, Research, RVV, Death, Doctor of Philosophy, Trial of the century, Cough, CDC, Harvard University, Fever, Safety, Therapy, Disorder, FDA, Economics, Hospital, Pharmaceutical industry

Following the submission of the Type C meeting request package, the Company expects to hear from the FDA on a firm date for the meeting.

Key Points: 
  • Following the submission of the Type C meeting request package, the Company expects to hear from the FDA on a firm date for the meeting.
  • The CDC estimates that 7.5 percent of U.S. adults have long COVID symptoms1.
  • Currently, the Company is exploring the use of Bucillamine as a potential treatment for long COVID.
  • The Company is advancing the clinical development of Bucillamine by leveraging the published research and data from its previous Phase 3 clinical trial (the “Study”) and is finalizing the regulatory and clinical package that includes a proposed clinical study for long COVID to present to the FDA.

NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES

Retrieved on: 
Wednesday, March 27, 2024
WEE1, Netherlands Cancer Institute, Bernards, Cell, Professor, Malignancy, Neoplasm, Cancer, Death, Cancer Discovery (journal), Vaccine

PASADENA, CA, March 27, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, announced today publication of pre-clinical data in the online journal, Cancer Discovery, showing that its lead clinical compound, LB-100, can force cancer cells to give up their cancer-causing properties in a paper entitled “Paradoxical activation of oncogenic signaling as a cancer treatment strategy.” The finding opens a potentially new treatment strategy in addition to LIXTE’s current three clinical trials.

Key Points: 
  • The deliberate hyper-activation of cancer signals becomes lethal when combined with an inhibitor of the WEE1 kinase.
  • This well-tolerated combination proved to be highly effective in killing colon cancer cells in animal models of cancer and in cell culture.
  • Resistance to LB-100 therapy, however, has been shown to be associated with cancer cells becoming less malignant.
  • Although cancer-causing signals force cancer cells to become more cancerous, the hyper-activation of these signals by LB-100 forces cancer cells to suppress these signals and thus become less cancerous.